Drug data last refreshed 21h ago · AI intelligence enriched 1mo ago
Imodium Multi-Symptom Relief is an oral tablet combining loperamide hydrochloride (an antidiarrheal agent) and dimethicone (an anti-flatulence agent) for symptomatic relief of diarrhea and associated gastrointestinal discomfort. The combination targets both primary diarrheal symptoms and secondary gas-related symptoms in a single formulation. This is an over-the-counter product indicated for acute diarrhea management in adult populations.
This OTC product faces moderate competitive pressure (30/100) with declining exclusivity, suggesting brand team focus on market defense and line extensions rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Imodium Multi-Symptom Relief offers exposure to OTC brand management, consumer marketing, and retail channel strategy in a mature product category. Career growth depends on driving innovation through line extensions, market share defense, and consumer engagement rather than clinical expansion.
Worked on IMODIUM MULTI-SYMPTOM RELIEF at Kenvue Brands? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.